Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 26815

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Therapeutic
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26815

License Grant
The University hereby grants to Licensee, subject to all the terms and conditions of this Agreement, a non-transferable worldwide exclusive license for the term defined by this agreement to make, have made, use, sell and practice the inventions and to commercialize the research, in each case for therapeutic or diagnostic purposes.
License Property
Licensed Products shall mean all products for therapeutic or diagnostic uses that may derive from or which result from the manufacture and production or use of a claim of the licensed patents, wherever sold.

The Licensed Patents involved are as follows

US Patent Number 5,101,072, Issued 3/3/1992 N-methyl and N-(2-Clorethyl) sulfonylhydrazines as Antineoplastic and Antitrypanosomal Agents
US Patent Number 5,214,068, Issued 5/25/1993 Sulfonylhydrazines and Their Use as Antineoplastic Agents and asAntitrypanosomal Agents
US Patent Number 5,256,820, Issued 10/26/1993 1-Alkyl-2-Acyl-1, 2-Disulfonylhydrazines

Additional Technologies Antitumor 2-2 -aminocarbonyl -1-1, 2-bis (methylsulfonyl) -1-2-chloroethyl) hydrazines; (OCR 512)
2-Alkoxcarbonyl-and 2-aryloxycarbonyl -1, 2-bis (methylsulfonyl) – 1-
(2chloroethyl) hyrazines with Antineoplastic Activity (OCR 524)
Synthesis of 3- and 5-methylaminopyridine-2 -carboxaldehyde Thiosemicarbazones (OCR 527)
Synthesis and Antitumor Active of 4- and 5-Substituted Derivatives of Isoquinoline-1-carboxaldehyde Thiosemicarbazone (OCR 528)
US Patent Application Serial Number 098,650 Novel L-2', 3'-Dideoxy Nucleoside Analogs as Anti-Hepatitis B (HBV) Agents
Additional Technology
Inhibition of Human Hepatitis B virus Replication by 3'-Thia 2', 3'-dideoxycytidine and its Derivatives (OCR 340)

IPSCIO Record ID: 26805

License Grant
License grants a non-transferable worldwide exclusive license to a U.S. corporation from a U.S. University. Technology licensed includes the following US Patent Number 5,101,072, Issued 3/3/1992 N-methyl and N-(2-Clorethyl) sulfonylhydrazines as Antineoplastic and Antitrypanosomal Agents.
License Property
Patent Listing

US Patent Number 5,101,072, Issued 3/3/1992

N-methyl and N-(2-Clorethyl) sulfonylhydrazines as Antineoplastic and Antitrypanosomal Agents

US Patent Number 5,214,068, Issued 5/25/1993

Sulfonylhydrazines and Their Use as Antineoplastic Agents and as Antitrypanosomal Agents

US Patent Number 5,256,820, Issued 10/26/1993

1-Alkyl-2-Acyl-1, 2-Disulfonylhydrazines

Additional Technologies

Antitumor 2-2 -aminocarbonyl -1-1, 2-bis (methylsulfonyl) -1-2-chloroethyl) ydrazines; (OCR 512)

2-Alkoxcarbonyl-and 2-aryloxycarbonyl -1, 2-bis (methylsulfonyl) – 1- (2chloroethyl) hyrazines with Antineoplastic Activity (OCR 524)

Synthesis of 3- and 5-methylaminopyridine-2 -carboxaldehyde Thiosemicarbazones (OCR 527)

Synthesis and Antitumor Active of 4- and 5-Substituted Derivatives of Isoquinoline-1-carboxaldehyde Thiosemicarbazone (OCR 528)

US Patent Application Serial Number 098,650

Novel L-2', 3'-Dideoxy Nucleoside Analogs as Anti-Hepatitis B (HBV) Agents

Additional Technology

Inhibition of Human Hepatitis B virus Replication by 3'-Thia 2', 3'-dideoxycytidine and its Derivatives (OCR 340)

Use of Porfiromycin, Dicoumoral, and X-irradiation for the treatment of solid tumors in Humans (CR 74)

Access to certain Data Concerning Clinical Studies carried out under the supervision of Yale faculty Concerning Porfiromycin

Licensed Products shall mean all products for therapeutic or diagnostic uses that may derive from or which result from the manufacture and production or use of a claim of the Licensed Patents, wherever sold.

Field of Use
Technology is relative to Anti-Hepatitis B Agents and treatment of solid tumors in humans.

IPSCIO Record ID: 172894

License Grant
The University and Licensee hereby agree to amend the License Agreement to reduce the earned royalties  payable on sublicense income,  and to make certain other changes to the License Agreement whereas the University and Licensee are parties to a License  Agreement, under which the University exclusively licensed to Licensee a series of University owned inventions relating to potential gene therapy vectors.
License Property
Patent Listing

US Patent Number 5,101,072, Issued 3/3/1992

N-methyl and N-(2-Clorethyl) sulfonylhydrazines as Antineoplastic and Antitrypanosomal Agents

US Patent Number 5,214,068, Issued 5/25/1993

Sulfonylhydrazines and Their Use as Antineoplastic Agents and as Antitrypanosomal Agents

US Patent Number 5,256,820, Issued 10/26/1993

1-Alkyl-2-Acyl-1, 2-Disulfonylhydrazines

Additional Technologies

Antitumor 2-2 -aminocarbonyl -1-1, 2-bis (methylsulfonyl) -1-2-chloroethyl) ydrazines; (OCR 512)

2-Alkoxcarbonyl-and 2-aryloxycarbonyl -1, 2-bis (methylsulfonyl) – 1- (2chloroethyl) hyrazines with Antineoplastic Activity (OCR 524)

Synthesis of 3- and 5-methylaminopyridine-2 -carboxaldehyde Thiosemicarbazones (OCR 527)

Synthesis and Antitumor Active of 4- and 5-Substituted Derivatives of Isoquinoline-1-carboxaldehyde Thiosemicarbazone (OCR 528)

US Patent Application Serial Number 098,650

Novel L-2', 3'-Dideoxy Nucleoside Analogs as Anti-Hepatitis B (HBV) Agents

Additional Technology

Inhibition of Human Hepatitis B virus Replication by 3'-Thia 2', 3'-dideoxycytidine and its Derivatives (OCR 340)

Use of Porfiromycin, Dicoumoral, and X-irradiation for the treatment of solid tumors in Humans (CR 74)

Access to certain Data Concerning Clinical Studies carried out under the supervision of Yale faculty Concerning Porfiromycin

Licensed Products shall mean all products for therapeutic or diagnostic uses that may derive from or which result from the manufacture and production or use of a claim of the Licensed Patents, wherever sold.

Technology is relative to Anti-Hepatitis B Agents and treatment of solid tumors in humans.

Term Agreement lasts through expiration of last patent.

Territory Worldwide

5,101,072 The present invention is directed to novel sulfonylhydrazines and their use as antineoplastic agents. The present invention also concerns methylating agents, especially N-methyl-N- sulfonylhydrazines, and their use as antineoplastic and trypanocidal agents.  The present invention also relates to a method of treating cancer (e.g., leukemia, lymphoma, breast carcinoma, colon carcinoma and lung carcinoma), in a warm blooded animal patient, e.g., a human, by administering to such patient an antineoplastic effective amount of the aforesaid sulfonylhydrazine.

5,256,820 This invention generally concerns compounds having antineoplastic activity and methods of therapy using these compounds.

5,101,072 Sulfonylhydrazines of the formula RSO.sub.2 N(CH.sub.2 CH.sub.2 X)N(SO.sub.2 CH.sub.3).sub.2, wherein R is an alkyl or an aryl and X is a halogen or OSO.sub.2 Y, wherein Y is an alkyl or an aryl. Such sulfonylhydrazines are useful in treating cancer. Methylating agents of the formula (a) R'SO.sub.2 N(CH.sub.3)N(SO.sub.2 CH.sub.3).sub.2, wherein R' is an alkyl or an aryl and (b) R'SO.sub.2 N(CH.sub.3)N(CH.sub.3)SO.sub.2 R, wherein R is an alkyl or an aryl. Such methylating agents are useful as antitrypanosomal and anticancer agents.

5,256,820  Novel antineoplastic 1-alkyl-2-acyl-1,2-disulfonylhydrazine having the following formula and methods of therapy using those antineoplastic compounds ##STR1## where R.sub.1 and R.sub.2 are (independently) alkyl, cycloalkyl, aryl, aralkyl or heteroaryl. X is an acyl group, and Z is an alkyl or a haloalkyl group.

Field of Use
This agreement pertains to the drug industry relating to gene therapy vectors.

Technology is relative to Anti-Hepatitis B Agents and treatment of solid tumors in humans.

IPSCIO Record ID: 362454

License Grant
Pursuant to the terms of a certain License Agreement, by and between a University, the Licensors Designee in this agreement, and Licensor, the University and Licensor have agreed to grant Licensee a sublicense in certain inventions relating to ß-L-FD4C.

Licensor hereby grants to Licensee a non-transferable, worldwide, exclusive license under the Licensed Technology to make, have made, import, export, use, sell and have sold Licensed Products and practice the Inventions.

License Property
The University has licensed to Licensor certain inventions relating to, among other things, potential anti-viral compounds, including ß-L-FD4C.

The patents include
Novel L-23-Dideoxy Nucleoside Analogs as Anti-Hepatitis (HBV) Agents;
Reduced Toxicity Compositions and Methods for Treating HIV Infections; and,
Process for High Yield Diastereoselective Syntheses of Dideoxvnucleotides.

Field of Use
The field of use includes HIV treatments.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.